PMID: 7400341May 1, 1980

Fibrin cross-linking in congenital factor XIII deficiency

Journal of Clinical Pathology
F Rodeghiero, T Barbui


Homozygous patients with factor XIII deficiency are devoid of immunologically identifiable A protein, the active enzymatic component. Quantitative studies of transamidase activity of the factor are available in only a few cases, and the fibrin cross-linking pattern is not well known. The present paper deals with the quantitative estimation of factor XIII transamidase activity (dansylcadaverine system), factor XIII molecular subunits, and the corresponding fibrin cross-linking pattern in seven homozygous patients with factor XIII deficiency. The results indicate that transamidase activity was present in all patients, and the range was 0.5-1.7%. The pattern of fibrin stabiisation showed an absence of cross-linking in two patients, the presence of gamma-gamma-dimers (traces) in four, and gamma-gamma-dimers plus incomplete alpha-polymers (traces) in one patient. In conclusion, the homozygous patients reported here were not completely devoid of functioning factor XIII.


Feb 1, 1978·British Journal of Haematology·T BarbuiC M Umana
Mar 1, 1977·Headache·G NatteroF Ceresa
Jan 1, 1972·Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum·C B Laurell
Feb 27, 1974·Biochemical and Biophysical Research Communications·L LorandP Stenberg
Oct 1, 1973·The Journal of Clinical Investigation·E D IsraelsL G Israels
Dec 8, 1972·Annals of the New York Academy of Sciences·F Duckert
Dec 8, 1972·Annals of the New York Academy of Sciences·E Ikkala
Jan 1, 1972·Clinica Chimica Acta; International Journal of Clinical Chemistry·J S Finlayson, R O Morton
Dec 8, 1972·Annals of the New York Academy of Sciences·S I Chung
Jun 1, 1969·The Journal of Clinical Investigation·L LorandH L Nossel
Apr 1, 1971·Proceedings of the National Academy of Sciences of the United States of America·J J PisanoY Nagai
Dec 1, 1970·British Journal of Haematology·K J Miloszewski, M S Losowsky
Apr 1, 1964·Archives of Biochemistry and Biophysics·L Lorand, K KONISHI


Oct 1, 1990·British Journal of Haematology·F Rodeghiero, A Tosetto
Jul 1, 1994·Protein Science : a Publication of the Protein Society·L C PedersenR E Stenkamp
Oct 1, 1989·American Journal of Reproductive Immunology : AJRI·J Kappelmayer, R Adány
Nov 19, 2013·Journal of the European Academy of Dermatology and Venereology : JEADV·D TöröcsikR Adány
Nov 8, 2014·Haemophilia : the Official Journal of the World Federation of Hemophilia·C AshleyD J Nugent
Dec 10, 2009·Blood·Kohji KasaharaA Ichinose
May 4, 1999·The Journal of Experimental Medicine·T NollH M Piper
Dec 30, 2018·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·L Lorand, Siiri E Iismaa
Aug 8, 2015·Molecular Genetics & Genomic Medicine·Anne ThomasJ Oldenburg
Jan 15, 2014·Haemophilia : the Official Journal of the World Federation of Hemophilia·V L SimhadriC Kimchi-Sarfaty
May 19, 2017·Haemophilia : the Official Journal of the World Federation of Hemophilia·V IvaškevičiusJ Oldenburg
Feb 1, 2003·Haemophilia : the Official Journal of the World Federation of Hemophilia·G PernodB Polack

Related Concepts

Enzyme Activation
Factor XIII A-Chain
Factor Xiii Deficiency
Antithrombin I
Plasma Protein Binding Capacity

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.